6318-56-5

Usage

Uses

Used in Pharmaceutical Synthesis:
5-Aminobenzene-1,3-diol hydrochloride is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Enzyme Inhibition Studies:
In the field of biochemistry, 5-Aminobenzene-1,3-diol hydrochloride is utilized as a research tool for studying enzyme inhibition. Its interaction with enzymes can provide valuable insights into the mechanisms of enzyme function and inhibition, contributing to the development of novel therapeutic agents.
Used in DNA Damage Research:
5-Aminobenzene-1,3-diol hydrochloride is employed in research focused on DNA damage and repair mechanisms. Its ability to interact with DNA can help scientists understand the processes involved in DNA damage and the potential for developing treatments to mitigate its effects.
Used in Neurodegenerative Disease Treatment Development:
In the medical field, 5-Aminobenzene-1,3-diol hydrochloride is a key ingredient in the development of potential treatments for neurodegenerative diseases. Its role in these treatments is attributed to its potential to target specific pathways and mechanisms involved in the progression of such diseases.
It is crucial to handle 5-Aminobenzene-1,3-diol hydrochloride with care and follow proper laboratory safety practices to ensure the safety of researchers and the integrity of experiments.

InChI:InChI=1/C6H7NO2.ClH/c7-4-1-5(8)3-6(9)2-4;/h1-3,8-9H,7H2;1H

Upstream product

• 108-73-6 3,5-dihydroxyphenol 

Downstream Products

• 1398702-11-8 3,5-bis(tert-butyldimethylsilyloxy)aniline 
• 64339-43-1 5-iodoresorcinol 
• 114154-61-9 3α-tert-butyldimethylsilyloxy-12,13-epoxytrichothec-9-ene-4β,15-diol 4β,15-di-(3-azido-5-methoxyphenoxy)acetate 
• 114123-85-2 3α-tert-butyldimethylsilyloxy-12,13-epoxytrichothec-9-ene-4β,15-diol 15-acetate 4β-<4-(3-azido-5-methoxyphenoxy)>butyrate 
• 114123-84-1 3α-tert-butyldimethylsilyloxy-12,13-epoxytrichothec-9-ene-4β,15-diol 15-acetate 4β-(3-azido-5-methoxyphenoxy)acetate 
• 114091-21-3 C₃₂H₄₅N₃O₉Si 
• 114091-22-4 12,13-epoxytrichothec-9-ene-3α,4β,15-triol 4β-acetate 15-(3-azido-5-methoxyphenoxy)acetate 
• 114091-06-4 methyl 4-(3-azido-5-methoxyphenoxy)butyrate 
• 114091-05-3 methyl 4-(3-azido-5-hydroxyphenoxy)butyrate 
• 114091-08-6 4-(3-azido-5-methoxyphenoxy)butyric acid 
• 114091-04-2 methyl (3-azido-5-methoxyphenoxy)acetate 
• 114091-07-5 (3-azido-5-methoxyphenoxy)acetic acid 
• 114970-03-5 methyl (3-azido-5-hydroxyphenoxy)acetate 
• 51642-28-5 5-azidobenzene-1,3-diol 

Relevant academic research and scientific papers

A Bimetallic Metal–Organic Framework Encapsulated with DNAzyme for Intracellular Drug Synthesis and Self-Sufficient Gene Therapy

Although chemotherapy is one of the most widely used cancer treatments, there are serious side effects, drug resistance, and secondary metastasis. To address these problems, herein we designed a bimetallic metal–organic framework (MOF) encapsulated with DNAzyme for co-triggered in situ cancer drug synthesis and DNAzyme-based gene therapy. Once in cancer cells, MOFs would disassemble and liberate copper ions, zinc ions, and DNAzyme under the acidic environment of lysosomes. Copper ions can catalyze the synthesis of the chemotherapeutic drug through copper-catalyzed azide–alkyne cycloaddition (CuAAC) reaction after being reduced to CuI; zinc ions act as the cofactor to activate the cleavage activity of DNAzyme. The anticancer drug is synthesized intracellularly and can kill cancer cells on site to minimize side effects to normal organisms. The activated DNAzyme starts gene therapy to inhibit tumor proliferation and metastasis by targeting and cleaving oncogene substrates.

Synthesis and initial biological evaluation of myxocoumarin B

The myxocoumarins A and B from Stigmatella aurantiaca MYX-030 are natural products featuring unusual nitro- and long-chain alkyl substitution. While myxocoumarin A was shown to exhibit strong antifungal properties, the antifungal potential of myxocoumarin

A Biocompatible Heterogeneous MOF–Cu Catalyst for In Vivo Drug Synthesis in Targeted Subcellular Organelles

As a typical bioorthogonal reaction, the copper-catalyzed azide–alkyne cycloaddition (CuAAC) has been used for drug design and synthesis. However, for localized drug synthesis, it is important to be able to determine where the CuAAC reaction occurs in living cells. In this study, we constructed a heterogeneous copper catalyst on a metal–organic framework that could preferentially accumulate in the mitochondria of living cells. Our system enabled the localized synthesis of drugs through a site-specific CuAAC reaction in mitochondria with good biocompatibility. Importantly, the subcellular catalytic process for localized drug synthesis avoided the problems of the delivery and distribution of toxic molecules. In vivo tumor therapy experiments indicated that the localized synthesis of resveratrol-derived drugs led to greater antitumor efficacy and minimized side effects usually associated with drug delivery and distribution.

SUBSTITUTED AROMATIC COMPOUND, HYDROGELATION AGENT, HYDROGEL, AND METHOD FOR GELATING AQUEOUS SAMPLE

According to the present invention, a substituted aromatic compound represented by the following general formula (I) is provided. In general formula (I), A1, A2, and A3 each independently represent an aryl group substituted by a hydrophilic group.

Synthesis and biological activity of C-4 and C-15 Aryl azide derivatives of anguidine

Potential trichothecene photoaffinity reagents were prepared by coupling either the C-4 or C-15 alcohols derived from anguidine with (3-azido-5-methoxyphenoxy) acetic acid, 4-(3-azido-5-methoxyphenoxy)butyric acid, or N-(3-azido-5-methoxyphenyl) N'-(carbo